Granissetrom Kabi

Granissetrom Kabi is a prescription injectable solution containing granisetron hydrochloride. The sterile liquid is administered intravenously and belongs to the 5‑HT3 receptor antagonist class of antiemetics. Marketed in the European Union, it is intended for use under medical supervision to help prevent nausea and vomiting related to chemotherapy or postoperative recovery. The product does not contain a specified strength, and dosing is determined by treating physician based on clinical guidelines.

Granissetrom Kabi is used clinically to reduce the risk of nausea and vomiting in specific treatment settings.

- Prevention of chemotherapy‑induced nausea and vomiting (CINV). - Prevention of postoperative nausea and vomiting (PONV). - Adjunct therapy for patients receiving highly emetogenic chemotherapy. - Use in combination with other antiemetic agents when recommended by guidelines. - Management of nausea associated with radiation therapy. - Use in patients who have experienced breakthrough nausea despite standard prophylaxis.

The safety profile of Granissetrom Kabi includes both frequently observed and less common adverse reactions.

Common: - Headache. - Constipation. - Dizziness. - Fatigue. - Injection‑site pain or erythema.

Serious: - Anaphylactic reaction. - Cardiac arrhythmia or severe hypotension. - Serotonin syndrome (rare).

Before prescribing Granissetrom Kabi, clinicians should consider several precautionary factors to ensure safe use.

- Assess patient history for hypersensitivity to granisetron or other 5‑HT3 antagonists. - Use caution in patients with prolonged QT interval or cardiac conduction disorders. - Evaluate hepatic or renal impairment, as dose adjustment may be required. - Monitor for signs of serotonin syndrome when combined with serotonergic drugs. - Consider pregnancy and breastfeeding status; safety data are limited. - Review concomitant medications that may affect cardiac rhythm.

Granissetrom Kabi can interact with other medicines; some combinations should be avoided while others require careful monitoring.

Avoid: - Concurrent use with other 5‑HT3 antagonists (duplicate antiemetic effect). - Combination with drugs known to prolong QT interval (e.g., certain antiarrhythmics, antipsychotics).

Use with caution: - Serotonergic agents such as SSRIs, SNRIs, tramadol, or linezolid (risk of serotonin syndrome). - CYP3A4 inhibitors or inducers that may alter granisetron plasma levels. - Other antiemetics that may increase cardiac risk.